Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Importance: Increasing levels of high-density lipoprotein (HDL) cholesterol through pharmacologic inhibition of cholesteryl ester transfer protein (CETP) is a potentially important strategy for prevention and treatment of cardiovascular disease (CVD). Objective: To use genetic variants in the CETP gene to assess potential risks and benefits of lifelong lower CETP activity on CVD and other outcomes. Design, Setting, and Participants: This prospective biobank study included 151 217 individuals aged 30 to 79 years who were enrolled from 5 urban and 5 rural areas of China from June 25, 2004, through July 15, 2008. All participants had baseline genotype data, 17 854 of whom had lipid measurements and 4657 of whom had lipoprotein particle measurements. Median follow-up of 9.2 years (interquartile range, 8.2-10.1 years) was completed January 1, 2016, through linkage to health insurance records and death and disease registries. Exposures: Five CETP variants, including an East Asian loss-of-function variant (rs2303790), combined in a genetic score weighted to associations with HDL cholesterol levels. Main Outcomes and Measures: Baseline levels of lipids and lipoprotein particles, cardiovascular risk factors, incidence of carotid plaque and predefined major vascular and nonvascular diseases, and a phenome-wide range of diseases. Results: Among the 151 217 individuals included in this study (58.4% women and 41.6% men), the mean (SD) age was 52.3 (10.9) years. Overall, the mean (SD) low-density lipoprotein (LDL) cholesterol level was 91 (27) mg/dL; HDL cholesterol level, 48 (12) mg/dL. CETP variants were strongly associated with higher concentrations of HDL cholesterol (eg, 6.1 [SE, 0.4] mg/dL per rs2303790-G allele; P = 9.4 × 10-47) but were not associated with lower LDL cholesterol levels. Within HDL particles, cholesterol esters were increased and triglycerides reduced, whereas within very low-density lipoprotein particles, cholesterol esters were reduced and triglycerides increased. When scaled to 10-mg/dL higher levels of HDL cholesterol, the CETP genetic score was not associated with occlusive CVD (18 550 events; odds ratio [OR], 0.98; 95% CI, 0.91-1.06), major coronary events (5767 events; OR, 1.08; 95% CI, 0.95-1.22), myocardial infarction (3118 events; OR, 1.14; 95% CI, 0.97-1.35), ischemic stroke (13 759 events; OR, 0.94; 95% CI, 0.86-1.02), intracerebral hemorrhage (6532 events; OR, 0.94; 95% CI, 0.83-1.06), or other vascular diseases or carotid plaque. Similarly, rs2303790 was not associated with any vascular diseases or plaque. No associations with nonvascular diseases were found other than an increased risk for eye diseases with rs2303790 (4090 events; OR, 1.43; 95% CI, 1.13-1.80; P = .003). Conclusions and Relevance: CETP variants were associated with altered HDL metabolism but did not lower LDL cholesterol levels and had no significant association with risk for CVD. These results suggest that in the absence of reduced LDL cholesterol levels, increasing HDL cholesterol levels by inhibition of CETP may not confer significant benefits for CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · cited 1×
“Genotyping and Lipid and LipoproteinMeasurements Five CETP gene variants (rs3764261, rs1800775, rs708272, rs9939224, and rs2303790; eTable 1 in the Supplement) were selected on the basis of previously reported associations withHDLcholesterol andCETPactivity.(11,19,28)Genotypingwas conducted in 151 217 individuals by u…”
MethodSelf-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“The first CETP inhibitor assessed in phase 3 trials, torcetrapib, was associated with increased CVD risk, probably owing to off-target effects.(4,5) Subsequent trials of dalcetrapib (which had only modest effects on HDL cholesterol) or evacetrapib (which increased HDL cholesterol levels substantially and lowered LDL c…”
BackgroundMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
(2007) · The Lancet · doi:10.1016/s0140-6736(07)61778-4 · Cited by 2,331 · cited 1×
“O bservational epidemiologic studies have reported that low plasma concentrations of high-density lipoprotein (HDL) cholesterol are an independent risk factor for occlusive cardiovascular disease (CVD), including coronary heart disease (CHD) and ischemic stroke.(1,2) Given these associations, therapeutic strategies to…”
BackgroundEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · cited 1×
“Subsequent trials of dalcetrapib (which had only modest effects on HDL cholesterol) or evacetrapib (which increased HDL cholesterol levels substantially and lowered LDL cholesterol levels) were stopped early for futility after 2 to 3 years of treatment in high-risk individuals.(6,7) A trial of the potent CETP inhibito…”
BackgroundHDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390 · cited 1×
“In a prospective study, HDL efflux capacity was inversely associated with atherosclerotic CVD risk in a population in which HDL cholesterol concentration had no significant association.(38) Another recent study reported that a functional variant in the scavenger receptor B1 (SRB1) gene, which blocks uptake of HDL-asso…”
BackgroundEffects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Chen, Z., Chen, J., Collins, R., Guo, Y., Peto, R., Wu, F., Li, L., & on behalf of the China Kadoorie Biobank (CKB) collaborative group (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyr120 · Cited by 1,034
Self-citationPlasma cholesteryl ester transfer protein
Tall, A. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36957-1 · Cited by 953
Evacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801 · cited 3×
“Subsequent trials of dalcetrapib (which had only modest effects on HDL cholesterol) or evacetrapib (which increased HDL cholesterol levels substantially and lowered LDL cholesterol levels) were stopped early for futility after 2 to 3 years of treatment in high-risk individuals.(6,7) A trial of the potent CETP inhibito…”
BackgroundResult
Cited by
Zheng, J., Haberland, V., Baird, D., Walker, V., Haycock, P., Hurle, M., Gutteridge, A., Erola, P., Liu, Y., Luo, S., et al. (2019) · doi:10.1101/627398 · Cited by 812
Self-citationMillwood, I. Y., Walters, R. G., Mei, X. W., Guo, Y., Yang, L., Bian, Z., Bennett, D. A., Chen, Y., Dong, C., Hu, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31772-0 · Cited by 514
Self-citationHolmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Self-citationCholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events
Armitage, J., Holmes, M. V., & Preiss, D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.072 · Cited by 140
“(14) China Kadoorie Biobank MVE 24,373/151,217 5 variants including loss of function rs2303790 CETP variants associated with higher HDL-C but not lower LDL-C.”
BackgroundSelf-citationBovijn, J., Krebs, K., Chen, C.-Y., Boxall, R., Censin, J. C., Ferreira, T., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6570 · Cited by 119
Self-citation
Metadata
- Authors
- Millwood, I. Y., Bennett, D. A., Holmes, M. V., Boxall, R., Guo, Y., Bian, Z., Yang, L., Sansome, S., Chen, Y., Du, H., Yu, C., Hacker, A., Reilly, D. F., Tan, Y., Hill, M. R., Chen, J., Peto, R., Shen, H., Collins, R., Clarke, R., Li, L., Walters, R. G., Chen, Z., & for the China Kadoorie Biobank Collaborative Group
- Venue
- JAMA Cardiology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-01-01
- Volume
- 3
- Issue
- 1
- Pages
- 34
- ISSN
- 2380-6583 (ISSN-L)
- OpenAlex
- W2770361731
- Cited by
- 81
- References
- 20
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults. https://app.cochat.ai/papers/10.1001/jamacardio.2017.4177
- The paper
- Millwood, I. Y., Bennett, D. A., Holmes, M. V., Boxall, R., Guo, Y., Bian, Z., Yang, L., Sansome, S., Chen, Y., Du, H., Yu, C., Hacker, A., Reilly, D. F., Tan, Y., Hill, M. R., Chen, J., Peto, R., Shen, H., Collins, R., . . . for the China Kadoorie Biobank Collaborative Group. (2018). Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults. JAMA Cardiology. https://doi.org/10.1001/jamacardio.2017.4177
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.